Biography
Dr. Michal Schnaider Beeri is an Associate Professor of Psychiatry. Dr. Beeri joined the faculty of Mount Sinai School of Medicine in 2001. Dr. Beeri's B.A. and Masters degrees were awarded Cum Laude. She received her Ph.D. in rehabilitation psychology from Bar Ilan University in Israel in 2000. She won the Brookdale Institute of Gerontology and Human Development, the Gonda Foundation, the International College of Geriatric Psychoneuropharmacology Young Investigator, and recently the Mount Sinai Academic Excellence Faculty Council awards. Specializing in geriatric psychology, her career has been fully devoted to the study of cognitive impairment, Alzheimer’s disease (AD), and dementia. A major focus of her work has been diabetes as a risk factor for dementia and AD. She received a Career Development Award from the NIA and a Young Investigator Award from the Alzheimer’s Association in recognition of her efforts to identify factors related to diabetes that are associated with dementia. She recently received an R01from the NIA to examine, in a large-scale study, the relationships between long-term diabetes characteristics and cognitive decline in a diabetic cohort in Tel-Aviv, Israel. Dr. Beeri's other major scientific focus is the neuropsychological and neurobiological aspects of cognition in the oldest-old. She has over 50 peer reviewed publications most of which are devoted to risk and protective factors against cognitive impairment, with an emphasis inthe oldest old.
Publications
Beeri MS, Goldbourt U. Late-life dementia predicts mortality beyond established midlife risk factors. American Journal of Geriatric Psychiatry 2010;.
Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, Grossman H, Haroutunian V. Less Alzheimer’s disease neuropathology in medicated hypertensive than non hypertensive persons. Neurology 2009; 72: 1720-1726.
Guerrero-Berroa E, Lou X, Schmeidler J, Rapp MA, Dahlman K, Grossman H, Haroutunian V, Beeri MS. The MMSE orientation in time domain is a strong predictor of cognitive decline in the elderly. International Journal of Geriatric Psychiatry 2009; 24: 1429-1437.
Haroutunian V, Beeri MS, Schmeidler J, Wysocki M, Purohit DP, Perl DP, Libow LS, Lesser GT, Maroukian M, Grossman HT. Role of the neuropathology of Alzheimer disease in dementia in the oldest old. Archives of Neurology 2008; 65: 1211-1217.
Beeri MS, Lee H, Cheng H, Wollman D, Silverman JM, Prohovnik I. Memory activation in healthy nonagenarians. Neurobiology of Aging 2010;.
Ravona-Springer R, Lou X, Schmeidler J, Wysocki M, Lesser GT, Rapp M, Dahlman K, Grossman HT, Haroutunian V, Beeri MS. Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dementia and Geriatric Cognitive Disorders 2010; 29: 68-74.
Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM, Purohit D, Lesser G, Grossman HT, Haroutunian V. Combination of insulin with other diabetes medication is associated with lower Alzheimer’s neuropathology. Neurology 2008; 71: 750-757.
Beeri MS, Schmeidler J, Sano M, Wang J, Lally R, Grossman H, Silverman JM. Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old. Neurology 2006; 67: 1006-1010.
Beeri MS, Rapp M, Silverman JM, Schmeidler J, Grossman HT, Fallon JT, Purohit DP, Perl DP, Siddiqui A, Lesser G, Rosendorff C, Haroutunian V. Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Neurology 2006; 66(9): 1399-1404.
Beeri MS, Davidson M, Silverman JM, Noy S, Schmeidler J, Ravona-Springer R, Sverdlick A, Davidson M. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004; 63: 1902-1907.
Clinical Trials
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Schnaider Beeri did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
50 East 98th Street Floor 1st Room Suite 1B
New York, NY 10029